Vascular remodeling in arteriovenous fistula treated with PDE5A inhibitors
Physiological Reports · 2025
DOI: 10.14814/phy2.70331 ↗At a glance
Journal article in Physiological Reports, 2025. Written by Maheshika Somarathna and 7 co-authors. Institution: Department of Medicine and Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama, USA. Major MEDLINE topics: Phosphodiesterase 5 Inhibitors, Sildenafil Citrate, Vascular Remodeling, Cyclic Nucleotide Phosphodiesterases, Type 5. Cited 3 times so far (Crossref); 48 references. The full text is freely available (open access, CC BY 4.0). Funded by: VA, NIH HHS, NHLBI NIH HHS.
Abstract (original language)
The arteriovenous fistula (AVF) is the lifeline for hemodialysis patients. However, there are currently no effective therapies promoting AVF maturation. AVF dilation by smooth muscle cell relaxation, through increased cyclic guanosine monophosphate (cGMP), is one potential mechanism to improve AVF remodeling. In this study, we examined the cGMP pathway and its inhibitor phosphodiesterase 5A (PDE5A) in rat, pig, and human AVF. We administered the PDE5A inhibitor, sildenafil, to rats with femoral AVFs and analyzed AVF histological and hemodynamic parameters. We observed that AVF creation increases PDE5A expression in rodent and porcine AVF models. Similarly, we observed an increase in PDE5A expression in the anastomotic regions of AVFs from hemodialysis patients when compared to pre‐AVF placement. Sildenafil‐treated rats showed significantly increased ultrasound‐derived AVF volumetric blood flow and increased MRI‐derived 3‐dimensional lumen diameter when compared to controls. MRI‐based computational fluid dynamics showed that sildenafil‐treated rats had increased anastomotic hemodynamics compared to control rats. Histology showed similar intimal hyperplasia in sildenafil‐treated and control rats. In conclusion, sildenafil treatment increases AVF vein outward expansion and blood flow without affecting the level of intimal hyperplasia. PDE5A inhibitors serve as a potential therapeutic approach to promote AVF maturation by enhancing outward vascular remodeling.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medicine and Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Department of Internal Medicine and Division of Nephrology and Hypertension, University of Utah, Salt Lake, Utah, USA.
- Veterans Affairs Medical Center, Salt Lake City, Utah, USA.
- Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, Utah, USA.
- Veterans Affairs Medical Center, Birmingham, Alabama, USA.
ORCID profiles: Timmy Lee
Funding
- VA
- NIH HHS
- NHLBI NIH HHS
- NCI NIH HHS
- BLRD VA
- NIDDK NIH HHS
- National Institutes of Health
- U.S. Department of Veterans Affairs
Cite
APA
Somarathna, M., Northrup, H., Ingle, K., Isayeva-Waldrop, T., Nguyen, N. T. N., Lose, B., Shiu, Y. T., & Lee, T. (2025). Vascular remodeling in arteriovenous fistula treated with PDE5A inhibitors. Physiological Reports. https://doi.org/10.14814/phy2.70331
Vancouver
Somarathna M, Northrup H, Ingle K, Isayeva-Waldrop T, Nguyen NTN, Lose B, et al. Vascular remodeling in arteriovenous fistula treated with PDE5A inhibitors. Physiological Reports. 2025. doi:10.14814/phy2.70331
BibTeX
@article{Somarathna2025,
author = {Somarathna, Maheshika and Northrup, Hannah and Ingle, Kevin and Isayeva-Waldrop, Tatyana and Nguyen, Nguyen Thuy Nhu and Lose, Bailey and Shiu, Yan-Ting and Lee, Timmy},
title = {Vascular remodeling in arteriovenous fistula treated with PDE5A inhibitors},
journal = {Physiological Reports},
year = {2025},
doi = {10.14814/phy2.70331}
}
EUVIMED